✦ LIBER ✦

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

✍ Scribed by Srikala S. Sridhar; Christina M. Canil; Kim N. Chi; Sebastien J. Hotte; Scott Ernst; Lisa Wang; Eric X. Chen; Agnes Juhasz; Yun Yen; Peter Murray; James A. Zwiebel; Malcolm J. Moore

Publisher: Springer
Year: 2010
Tongue: English
Weight: 298 KB
Volume: 67
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1389-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multiple-center phase II study of week

A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

✍ Jen-Shi Chen; Yen-Yang Chen; Jen-Sheng Huang; Kun-Yun Yeh; Ping-Tsung Chen; Wen- 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 181 KB

A multicenter phase II study of cisplati

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

✍ Véronique Diéras; JeanPaul Guastalla; JeanMarc Ferrero; Hervé Curé; Béatrice Web 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 208 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB